<DOC>
	<DOCNO>NCT00438022</DOCNO>
	<brief_summary>Atopic Dermatitis ( AD ) , also know eczema , skin disease cause skin hot , dry scaly , severe itching . There different kind eczema . Eczema herpeticum ( EH ) type eczema spread due underlie herpes virus infection . The purpose research study identify risk factor may cause EH .</brief_summary>
	<brief_title>Identifying Risk Factors Eczema Herpeticum Individuals With Atopic Dermatitis</brief_title>
	<detailed_description>AD characterize chronic skin inflammation infection . It hypothesize AD cause irritant environment symptom EH become bad stress change hormone level . This study examine skin cell collect study participant determine risk factor EH present people AD develop EH . This study examine dendritic cell ( DC ) skin blood study participant determine difference DCs study participant . This study recruit four type participant : - Group 1 include participant AD , EH , recurrent herpes simplex virus ( HSV ) - Group 2 include participant AD recur HSV infection without EH - Group 3 include participant AD without EH HSV infection - Group 4 include participant good general health without AD , EH , HSV infection At single study visit , skin blood collection occur .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Kaposi Varicelliform Eruption</mesh_term>
	<criteria>Inclusion Criteria Participants AD : Diagnosis AD define ADVN standardize diagnostic criterion fall one follow category : 1 . Recurrent , clinically manifest HSV infection EH 2 . Recurrent , clinically manifest HSV infection without EH 3 . No recurrent , clinically manifest HSV infection EH infection Inclusion Criteria All Participants Residing Germany Good general health atopic disease Caucasian Individuals 1860 year age Exclusion Criteria All Participants : Subjects atopy lack stringent AD feature , allow presumptive diagnosis AD Individuals 18 60 year age Systemic immunosuppressive drug chemotherapy 30 day prior study entry Oral topical corticosteroid ( include inhale agent ) , antibiotic , antiviral , antiinflammatory biologics ( e.g. , alefacept , etanercept ) , topical doxepin , topical coal tar preparation , topical phosphodiesterase inhibitor 14 day prior study entry Immunotherapy Antibiotics , antiviral , immune enhancer ( e.g. , imiquimod ) , calcineurin inhibitor within 7 day prior study entry Phototherapy ( e.g. , ultraviolet light B [ UVB ] , psoralen plus ultraviolet light A [ PUVA ] ) 30 day prior study entry Cancer , autoimmune disease , immunodeficiency Active fungal , bacterial , viral infection screen Any skin disease AD might compromise stratum corneum barrier ( e.g. , ichthyosis , bullous disease , psoriasis , skin cancer ) Mental illness history drug alcohol abuse , opinion investigator , would interfere participant 's ability comply study requirement Inability unwillingness subject give write informed consent Weigh le 40 kg ( 88.2 lb ) Anxiolytic agent Antidepressants Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Atopic Dermatitis</keyword>
	<keyword>Eczema Herpeticum</keyword>
</DOC>